Lumacaftor | List of Frontiers open access articles

Original Research

Published on 02 Aug 2021

Insights Into Patient Variability During Ivacaftor-Lumacaftor Therapy in Cystic Fibrosis

in Respiratory Pharmacology

Patrick O. Hanafin
Isabelle Sermet-Gaudelus
Matthias Griese
Matthias Kappler
Helmut Ellemunter
Carsten Schwarz
John Wilson
Marsha Tan
Tony Velkov
Gauri G. Rao

Frontiers in Pharmacology

doi 10.3389/fphar.2021.577263

5,129 views
18 citations

Original Research

Published on 19 Dec 2018

Variable Responses to CFTR Correctors in vitro: Estimating the Design Effect in Precision Medicine

in Pharmacology of Ion Channels and Channelopathies

Elizabeth Matthes
Julie Goepp
Carolina Martini
Jiajie Shan
Jie Liao
David Y. Thomas
John W. Hanrahan

Frontiers in Pharmacology

doi 10.3389/fphar.2018.01490

4,092 views
20 citations

Opinion

Published on 25 Feb 2022

What Is the Potential for Lumacaftor as a Chemical Chaperone in Promoting hERG Trafficking?

in Cardiovascular Therapeutics

Zequn Zheng
Yongfei Song
Jiangfang Lian

Frontiers in Cardiovascular Medicine

doi 10.3389/fcvm.2022.801927

3,367 views
8 citations

Brief Research Report

Published on 24 Jul 2020

CFTR Modulators Dampen Aspergillus-Induced Reactive Oxygen Species Production by Cystic Fibrosis Phagocytes

in Fungal Pathogenesis

Alexander J. Currie
Ellen T. Main
Heather M. Wilson
Darius Armstrong-James
Adilia Warris

Frontiers in Cellular and Infection Microbiology

doi 10.3389/fcimb.2020.00372

6,575 views
32 citations

Original Research

Published on 15 Nov 2021

Long-Term Outcomes in Real Life of Lumacaftor–Ivacaftor Treatment in Adolescents With Cystic Fibrosis

in Pediatric Pulmonology

Stéphanie Bui
Alexandra Masson
Raphaël Enaud
Léa Roditis
Gaël Dournes
François Galode
Cyrielle Collet
Emmanuel Mas
Jeanne Languepin
Michael Fayon

Frontiers in Pediatrics

doi 10.3389/fped.2021.744705

4,639 views
17 citations

Original Research

Published on 04 Jul 2018

Molecular Mechanism of Action of Trimethylangelicin Derivatives as CFTR Modulators

in Pharmacology of Ion Channels and Channelopathies

Onofrio Laselva
Giovanni Marzaro
Christian Vaccarin
Ilaria Lampronti
Anna Tamanini
Giuseppe Lippi
Roberto Gambari
Giulio Cabrini
Christine E. Bear
Adriana Chilin

Frontiers in Pharmacology

doi 10.3389/fphar.2018.00719

9,092 views
31 citations

Articles

Insights Into Patient Variability During Ivacaftor-Lumacaftor Therapy in Cystic Fibrosis

Variable Responses to CFTR Correctors in vitro: Estimating the Design Effect in Precision Medicine

What Is the Potential for Lumacaftor as a Chemical Chaperone in Promoting hERG Trafficking?

CFTR Modulators Dampen Aspergillus-Induced Reactive Oxygen Species Production by Cystic Fibrosis Phagocytes

Long-Term Outcomes in Real Life of Lumacaftor–Ivacaftor Treatment in Adolescents With Cystic Fibrosis

Molecular Mechanism of Action of Trimethylangelicin Derivatives as CFTR Modulators